Prometheus Laboratories introduced three new laboratory diagnostic products aimed at nonalcoholic steatohepatitis, or NASH, Crohn’s Disease, and adult inflammatory bowel disease. The FibroSpect NASH test is designed to help clinicians stratify NASH patients by risk based on the severity of their liver fibrosis. The noninvasive serum test was validated with well-characterized and clinically confirmed NASH patients.
The Prometheus Monitr Crohn’s Disease is a serum test for measuring and monitoring serum status in Crohn’s disease patients. Traditionally, Crohn’s Disease has only been diagnosed invasively through colonoscopy and endoscopy. The Monitor Crohn’s Disease, which can be used as an adjunct to endoscopy or by itself between endoscopies, demonstrated high accuracy and concordance rates with endoscopically visual mucosal disease during clinical validation, Prometheus said.
The Prometheus Anser UST is a drug-monitoring test for use with adult inflammatory bowel disease patients treated with Stelara, also known as ustekinumab. As a drug-tolerant test, Prometheus Anser UST measures both serum drug concentrations and antidrug antibody levels from a single serum sample to help physicians monitor this biologic therapy and optimize treatment.